Registered title, quoted from ClinicalTrials.gov
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07483554, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.
Inclusion criterion 8
Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment.
Inclusion criterion 7
Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug.
Exclusion criterion 2
Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.
Exclusion criterion 3
Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
Exclusion criterion 4
Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.
Exclusion criterion 5
Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.
Exclusion criterion 8
Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug.
Exclusion criterion 9
History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.
Exclusion criterion 10
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Inclusion criterion 4
At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Inclusion criterion 2
Pregnant or lactating female subjects.
Exclusion criterion 24
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07483554, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion criteria:
- Signed written informed consent, willing and able to comply with the protocol-specified visits and related procedures.
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
- Age ≥ 18 years, no gender restrictions.
- An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Expected survival ≥ 12 weeks.
- Adequate bone marrow and organ function.
- Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment.
- Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.
Exclusion criteria:
- Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.
- Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug.
- Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.
- Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
- Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.
- Planning to receive other anti-tumor treatments during the period of treatment with the investigational drug.
- Received any live vaccine within 4 weeks prior to the first dose of the investigational drug or planning to receive any live vaccine during the study.
- Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.
- Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug.
- History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.
- Presence of pyloric obstruction and/or persistent recurrent vomiting.
- Post-procedure of stent implantation in the digestive tract or trachea.
- Symptomatic central nervous system metastasis.
- Bone metastasis with risk of paraplegia.
- Interstitial lung disease requiring steroid treatment, or history of interstitial lung disease, non-infectious pneumonia, severe impairment of pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having these diseases during the screening period.
- Presence of uncontrolled disease.
- History of other primary malignant tumors.
- Known history of immunodeficiency.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Previous treatment with topoisomerase inhibitor-based antibody-drug conjugates.
- For subjects receiving drug treatment, a history of allergy to the corresponding drug or formulation.
- For subjects receiving drug treatment, contraindications for the corresponding drug.
- For subjects receiving drug treatment, a history of permanent discontinuation of the corresponding drug due to related adverse reactions.
- Pregnant or lactating female subjects.
- Other conditions deemed unsuitable for participation in this study by the investigator.
Quoted from ClinicalTrials.gov, NCT07483554, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07483554, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.